NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

NRx Pharmaceuticals, Inc.

A pharmaceutical company focused on developing innovative therapies for the treatment of central nervous system disorders and life-threatening pulmonary conditions.

NRx Pharmaceuticals

Understanding the role of Vasoactive Intestinal Peptide (VIP) in treating COVID-19

NeuroRx: Understanding our science

NRx Pharmaceuticals, Inc. draws upon decades of collective, scientific, and drug-development experience to address very high unmet needs of patients and bring improved health to patients. The U.S. Food and Drug Administration (“FDA”) has additionally granted Breakthrough Therapy designation, a Special Protocol Agreement, and a Biomarker Letter of Support for NRX-101, an investigational medicine for the treatment of severe bipolar depression in patients with acute suicidal ideation and behavior (ASIB) after initial stabilization with ketamine or other effective therapy. NRx Pharmaceuticals is led by executives who have held leadership roles at Lilly, Pfizer, and Novartis as well as major investment banking institutions.

COM:NRXPHARMA

NRx Pharmaceuticals

Last Close

1.23

22/11 21:00

Market Cap

25.25M

Beta: -

Volume Today

79.66K

Avg: -